Literature DB >> 25342402

Use of the Trauma Embolic Scoring System (TESS) to predict symptomatic deep vein thrombosis and fatal and non-fatal pulmonary embolism in severely injured patients.

K M Ho1, S Rao2, K J Rittenhouse3, F B Rogers4.   

Abstract

Fatal pulmonary embolism is the third most common cause of death after major trauma. We hypothesised that the Trauma Embolic Scoring System (TESS) would have adequate calibration and discrimination in a group of severely injured trauma patients in predicting venous thromboembolism (VTE), and could be used to predict fatal and non-fatal symptomatic pulmonary embolism. Calibration and discrimination of the TESS were assessed by the slope and intercept of the calibration curve and the area under the receiver operating characteristic curve, respectively. Of the 357 patients included in the study, 74 patients (21%) developed symptomatic VTE after a median period of 14 days following injury. The TESS predicted risks of VTE were higher among patients who developed VTE than those who did not (14 versus 9%, P=0.001) and had a moderate ability to discriminate between patients who developed VTE and those who did not (area under the receiver operating characteristic curve 0.71, 95% confidence interval 0.65 to 0.77). The slope and intercept of the calibration curve were 2.76 and 0.34, respectively, suggesting that the predicted risks of VTE were not sufficiently extreme and overall, underestimated the observed risks of VTE. Using 5% predicted risk of VTE as an arbitrary cut-point, TESS had a high sensitivity and negative predictive value (both ≥0.97) in excluding fatal and non-fatal pulmonary embolism. The TESS had a reasonable ability to discriminate between patients who developed VTE and those who did not and may be useful to select different strategies to prevent VTE in severely injured patients.

Entities:  

Keywords:  deep vein thrombosis; prediction; pulmonary embolism; risk assessment

Mesh:

Year:  2014        PMID: 25342402     DOI: 10.1177/0310057X1404200605

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  7 in total

1.  Incremental cost of venous thromboembolism in trauma patients with contraindications to prophylactic anticoagulation: a prospective economic study.

Authors:  Kwok M Ho; Frederick B Rogers; Jenny Chamberlain; Sana Nasim
Journal:  J Thromb Thrombolysis       Date:  2022-01-06       Impact factor: 2.300

2.  An abbreviated Caprini model for VTE risk assessment in trauma.

Authors:  Max D Hazeltine; Erin M Scott; Jon D Dorfman
Journal:  J Thromb Thrombolysis       Date:  2021-11-20       Impact factor: 2.300

Review 3.  Venous Thromboembolism in Trauma: The Role of Anticoagulation and Inferior Vena Cava Filters.

Authors:  Nicholas Xiao; Kush R Desai
Journal:  Semin Intervent Radiol       Date:  2021-04-15       Impact factor: 1.513

4.  Venous Thromboembolism in a Single Korean Trauma Center: Incidence, Risk Factors, and Assessing the Validity of VTE Diagnostic Tools.

Authors:  Sunjoo Boo; Hyunjin Oh; Kyungjin Hwang; Kyoungwon Jung; Jonghwan Moon
Journal:  Yonsei Med J       Date:  2021-06       Impact factor: 2.759

5.  Detailed assessment of benefits and risks of retrievable inferior vena cava filters on patients with complicated injuries: the da Vinci multicentre randomised controlled trial study protocol.

Authors:  Kwok M Ho; Sudhakar Rao; Stephen Honeybul; Rene Zellweger; Bradley Wibrow; Jeffrey Lipman; Anthony Holley; Alan Kop; Elizabeth Geelhoed; Tomas Corcoran
Journal:  BMJ Open       Date:  2017-07-12       Impact factor: 2.692

6.  Current and future burden of venous thrombosis: Not simply predictable.

Authors:  Luuk J J Scheres; Willem M Lijfering; Suzanne C Cannegieter
Journal:  Res Pract Thromb Haemost       Date:  2018-04-17

7.  Trauma Embolic Scoring System in military trauma: a sensitive predictor of venous thromboembolism.

Authors:  Patrick F Walker; Seth Schobel; Joseph D Caruso; Carlos J Rodriguez; Matthew J Bradley; Eric A Elster; John S Oh
Journal:  Trauma Surg Acute Care Open       Date:  2019-12-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.